Baxter Phillips
Director de Operaciones en LOBE SCIENCES LTD. .
Fortuna: 11 560 $ al 31/05/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Philip Young | M | 66 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 7 años |
Frederick Sancilio | M | 74 | - | |
Sherden Timmins | M | - |
Cambridge Allergy Ltd.
Cambridge Allergy Ltd. Pharmaceuticals: MajorHealth Technology Cambridge Allergy Ltd. operates as a biopharmaceutical company which manufactures medicines for food allergies. The company was founded by Sherden Timmins, Andrew Clark, and Pamela Ewan on December 7, 2015 and is headquartered in Cambridge, the United Kingdom. | 9 años |
Sandra Dosdall | F | 55 | - | |
Michael Petter | M | - | 3 años | |
Andrew Clark | M | - |
Cambridge Allergy Ltd.
Cambridge Allergy Ltd. Pharmaceuticals: MajorHealth Technology Cambridge Allergy Ltd. operates as a biopharmaceutical company which manufactures medicines for food allergies. The company was founded by Sherden Timmins, Andrew Clark, and Pamela Ewan on December 7, 2015 and is headquartered in Cambridge, the United Kingdom. | - |
Jonathan Milner | M | 59 |
Cambridge Allergy Ltd.
Cambridge Allergy Ltd. Pharmaceuticals: MajorHealth Technology Cambridge Allergy Ltd. operates as a biopharmaceutical company which manufactures medicines for food allergies. The company was founded by Sherden Timmins, Andrew Clark, and Pamela Ewan on December 7, 2015 and is headquartered in Cambridge, the United Kingdom. | 11 años |
Maghsoud Dariani | M | - | 4 años | |
Mathew Lee | M | 40 | 1 años | |
Sigurdur Martinsson | M | - |
Cambridge Allergy Ltd.
Cambridge Allergy Ltd. Pharmaceuticals: MajorHealth Technology Cambridge Allergy Ltd. operates as a biopharmaceutical company which manufactures medicines for food allergies. The company was founded by Sherden Timmins, Andrew Clark, and Pamela Ewan on December 7, 2015 and is headquartered in Cambridge, the United Kingdom. | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
David O'Flynn | M | - | - | |
Jonathan Gilbert | M | 52 | 2 años | |
M. Scott Salka | M | 62 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 2 años |
Matthew M. Loar | M | 61 | 2 años | |
Wendy Johnson | F | 72 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 5 años |
Kelley A. Wendt | F | 49 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 3 años |
David E. Bosher | M | 70 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 2 años |
John M. Barberich | M | 66 | 3 años | |
Bobby Sandage | M | 70 | 5 años | |
Alexander Gaidamaka | M | - |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | - |
Anthony Smithyman | M | 74 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 3 años |
Enda Kenny | M | - | 2 años | |
Julian P. Kirk | M | 50 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 2 años |
Florian Schönharting | M | 55 | - | |
Jeremy Curnock-Cook | M | 74 | 3 años | |
Thadd M. Vargas | M | 58 |
Neurogastrx, Inc.
Neurogastrx, Inc. BiotechnologyHealth Technology Neurogastrx, Inc. operates as a venture-stage biopharmaceutical company. The firm develops biopharmaceutical products for the treatment of gastrointestinal disorders. It offers NG101, a product for the treatment of gastroparesis. The company was founded by Cyril De Colle and Pankaj Jay Pasricha and is headquartered in Campbell, CA. | - |
Christian Hansen | M | 58 | - | |
Christopher Barry Wood | M | 78 | - | |
Brian Zasitko | M | 44 | 3 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Irlanda | 9 | 31.03% |
Estados Unidos | 9 | 31.03% |
Canadá | 8 | 27.59% |
Reino Unido | 4 | 13.79% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Baxter Phillips
- Red Personal